Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apria, Inc. stock logo
APR
Apria
$37.50
$37.45
$22.36
$40.00
$1.34BN/A682,285 shsN/A
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$29.45
-1.6%
$31.62
$21.39
$35.53
$4.82B0.731.82 million shs321,593 shs
Teleflex Incorporated stock logo
TFX
Teleflex
$111.28
-2.0%
$120.99
$111.12
$249.91
$4.92B1.08634,681 shs129,100 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$16.25
+0.7%
$16.50
$13.61
$30.36
$5.50BN/A28,866 shs8,659 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apria, Inc. stock logo
APR
Apria
0.00%0.00%0.00%0.00%0.00%
Option Care Health, Inc. stock logo
OPCH
Option Care Health
-1.48%-1.80%-5.97%-6.69%-3.01%
Teleflex Incorporated stock logo
TFX
Teleflex
+0.33%-5.27%-3.27%-12.24%-50.63%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
+3.00%+0.25%-3.06%-3.41%+1,613,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apria, Inc. stock logo
APR
Apria
N/AN/AN/AN/AN/AN/AN/AN/A
Option Care Health, Inc. stock logo
OPCH
Option Care Health
4.4471 of 5 stars
2.45.00.04.32.51.71.9
Teleflex Incorporated stock logo
TFX
Teleflex
4.8449 of 5 stars
4.04.02.53.91.91.71.3
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apria, Inc. stock logo
APR
Apria
0.00
N/AN/AN/A
Option Care Health, Inc. stock logo
OPCH
Option Care Health
2.88
Moderate Buy$35.5020.54% Upside
Teleflex Incorporated stock logo
TFX
Teleflex
2.09
Hold$159.6343.44% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
3.00
Buy$22.3337.44% Upside

Current Analyst Ratings Breakdown

Latest APR, TLX, TFX, and OPCH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$150.00 ➝ $130.00
7/15/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetSector Perform ➝ Sector Perform$145.00 ➝ $130.00
7/10/2025
Option Care Health, Inc. stock logo
OPCH
Option Care Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$38.00
7/9/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
7/3/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$23.00
6/18/2025
Option Care Health, Inc. stock logo
OPCH
Option Care Health
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$36.00
6/12/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$22.00
6/5/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00
5/5/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$140.00 ➝ $137.00
5/5/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$191.00 ➝ $173.00
5/2/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$150.00 ➝ $145.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apria, Inc. stock logo
APR
Apria
$1.15B1.17$5.27 per share7.12$1.12 per share33.48
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$5.00B0.96$1.59 per share18.47$8.25 per share3.57
Teleflex Incorporated stock logo
TFX
Teleflex
$3.05B1.61$24.89 per share4.47$92.11 per share1.21
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$516.72M10.64$0.12 per share137.23$1.12 per share14.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apria, Inc. stock logo
APR
Apria
$64.88MN/A0.0020.49N/A5.66%586.18%9.23%N/A
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$211.82M$1.2423.7523.371.844.12%16.90%7.00%7/30/2025 (Estimated)
Teleflex Incorporated stock logo
TFX
Teleflex
$69.68M$3.1735.127.331.784.96%14.73%8.79%7/30/2025 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$32.93MN/A0.0033.85N/AN/AN/AN/A8/20/2025 (Estimated)

Latest APR, TLX, TFX, and OPCH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Teleflex Incorporated stock logo
TFX
Teleflex
$3.36N/AN/AN/A$771.53 millionN/A
7/30/2025Q2 2025
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$0.40N/AN/AN/A$1.35 billionN/A
5/1/2025Q1 2025
Teleflex Incorporated stock logo
TFX
Teleflex
$2.88$2.91+$0.03$2.07$699.37 million$700.67 million
4/29/2025Q1 2025
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$0.36$0.40+$0.04$0.28$1.26 billion$1.33 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apria, Inc. stock logo
APR
Apria
N/AN/AN/AN/AN/A
Option Care Health, Inc. stock logo
OPCH
Option Care Health
N/AN/AN/AN/AN/A
Teleflex Incorporated stock logo
TFX
Teleflex
$1.361.22%N/A42.90%N/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A

Latest APR, TLX, TFX, and OPCH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/12/2025
Teleflex Incorporated stock logo
TFX
Teleflex
quarterly$0.341.09%5/20/20255/20/20256/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apria, Inc. stock logo
APR
Apria
8.58
1.09
1.06
Option Care Health, Inc. stock logo
OPCH
Option Care Health
0.82
1.54
1.02
Teleflex Incorporated stock logo
TFX
Teleflex
0.44
2.28
1.32
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.99
2.78
2.66

Institutional Ownership

CompanyInstitutional Ownership
Apria, Inc. stock logo
APR
Apria
N/A
Option Care Health, Inc. stock logo
OPCH
Option Care Health
98.05%
Teleflex Incorporated stock logo
TFX
Teleflex
95.62%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Apria, Inc. stock logo
APR
Apria
N/A
Option Care Health, Inc. stock logo
OPCH
Option Care Health
0.64%
Teleflex Incorporated stock logo
TFX
Teleflex
1.40%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Apria, Inc. stock logo
APR
Apria
6,08035.65 millionN/ANot Optionable
Option Care Health, Inc. stock logo
OPCH
Option Care Health
8,088163.75 million162.70 millionOptionable
Teleflex Incorporated stock logo
TFX
Teleflex
14,10044.19 million43.57 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A338.38 millionN/AN/A

Recent News About These Companies

William Blair Brokers Decrease Earnings Estimates for TLX
William Blair Has Negative Outlook of TLX FY2025 Earnings
Missing the first double on this biotech star
Gozellix Receives Permanent HCPCS Code
Telix shares jump 7% on big US news

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Apria stock logo

Apria NYSE:APR

Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. Apria, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana. As of March 29, 2022, Apria, Inc. operates as a subsidiary of Byram Healthcare Centers, Inc.

Option Care Health stock logo

Option Care Health NASDAQ:OPCH

$29.45 -0.49 (-1.64%)
As of 01:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.

Teleflex stock logo

Teleflex NYSE:TFX

$111.28 -2.31 (-2.03%)
As of 01:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$16.25 +0.11 (+0.68%)
As of 01:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.